Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...

chronic inflammatory demyelinating polyneuropathy in October 2021 and FNAIT in December 2023; US FDA Breakthrough Therapy designation for HDFN in February 2024 and for SjD in November 2024; EU EMA ...

KORU Medical Systems (NASDAQ:KRMD – Get Free Report) will release its earnings data after the market closes on Wednesday, ...

Keyword search terms used were; "chronic inflammatory demyelinating polyneuropathy" or "CIDP" or "chronic inflammatory polyneuropathy" or "autoimmune neuropathies" combined with "drug therapy" or ...

(ARGX) and Zai Lab Limited (ZLAB) announced that China’s National Medical Products Administration, NMPA, approved the supplemental ...

Nipocalimab is a fully human monoclonal antibody that blocks FcRn and decreases levels of circulating IgG antibodies.

One of its lead pipeline assets, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed in Phase 3 and Phase 2 ...

Suggested remit: To appraise the clinical and cost effectiveness of efgartigimod with recombinant human hyaluronidase PH20 within its marketing authorisation for treating chronic inflammatory ...

In July, she was informed that she was being dropped from a program that allowed her to get free infusions of a medication she needed to keep her chronic inflammatory bowel disease at bay.

Research Shows Therapeutic Virtual Yoga Program Can Be Effective for Chronic Low Back Pain Nov. 1, 2024 — Researchers found that a 12-week therapeutic virtual yoga program for chronic low back ...